Sage Journals: Discover world-class research

Abstract

Liver injury in Takayasu arteritis (TA) is a rare phenomenon. Most symptoms are nonspecific, and the exact pathogenesis remains to be elucidated. Early diagnosis and new treatment methods are important for an improved prognosis. A summary of the clinical information and mechanistic analyses may contribute to making an early diagnosis and development of new treatment methods. A PubMed search was conducted using the specific key words “Takayasu arteritis” and “liver” or “hepatitis” or “hepatic”. Symptoms and treatment of TA with an accompanying liver injury were reviewed retrospectively. Many factors are presumed to be involved in the mechanism of TA with liver injury, including the immune response, genes, infections, and gut microbiota. There are several lines of evidence indicating that immune dysfunction is the main pathogenic factor that triggers granuloma formation in TA patients. However, the role of genetics and infections has not been fully confirmed. Recently, the gut microbiota has emerged as an essential component in the process. We reviewed in detail the current concepts that support the complex pathogenesis of TA accompanied by liver injury, and we presented recent theories from the literature. Finally, we discussed future research directions of liver injury in TA.

Keywords

Takayasu arteritis granuloma liver granulomatous vasculitis inflammation gut microbiota

Introduction

Takayasu arteritis (TA) is a chronic nonspecific rare granulomatous vasculitis that predominantly occurs in the aorta and its main branches, such as carotid and vertebral arteries. Chronic inflammation may induce intimal hyperplasia and medial and intimal fibrosis, resulting in luminal stenosis.¹ Although the disease has a worldwide distribution, it is generally thought to be more common among Asian populations; the prevalence of TA is estimated to be 40 per million in Japan and 0.9 per million in US, and these variations may be derived from geographical and genetic differences between the populations.² TA is associated with a profound inflammatory process, which is possibly associated with an autoimmune disorder, but its precise etiology remains largely unknown.³ The clinical manifestations of TA are nonspecific and mainly depend on the type of lesion and the degree of inflammation.⁴ The 1990 American College of Rheumatology diagnosis criteria indicate that the lack of specific signs makes diagnosing this condition extremely challenging and that the disease activity is difficult to evaluate. Thus, early diagnosis and treatment of TA are a challenge, and the disease usually remains active throughout its course, leading to continuous damage accumulation and short- and long-term morbidity and mortality.^1,5

Current treatment strategies for TA mainly involve the use of corticosteroids. However, only a small number of patients are completely cured, and a sizable subset of patients relapse after treatment is gradually tapered.⁶ Thus, these relapsed patients require additional treatment options.⁷ Methotrexate (MTX) is an immunosuppressant that is most commonly used in these patients, and it has been reported to be a promising treatment option to achieve and maintain remission in refractory TA patients.⁸ Other drugs, such as leflunomide, have also been reported to cause quick induction and sustained remission of TA, especially in refractory cases, and therefore, these drugs should be considered to be an alternative treatment for TA.⁹ Additional biotherapeutic agents, such as tumor necrosis factor (TNF) inhibitors, have recently been approved for TA treatment. However, neither provide much more benefit than corticosteroids.^10,11 Therefore, early diagnosis and new treatment methods are important for improving patient prognosis. However, some TA patients initially present with liver injury, making an early diagnosis difficult. The purpose of this review was to investigate the clinical features and pathogenesis of liver injury in patients with TA.

Methods

A literature review was performed by searching PubMed using the key terms “Takayasu arteritis” and “liver” or “hepatitis” or “hepatic”. We identified five cases of abnormal liver function in TA (Table 1).^12–15

Table 1.

TA patients with accompanying liver injury.

Author	Age	Sex	Chief compliant	ALT	AST	ALP	GGT	Treatment	Outcome
Yotsuyanagi et al.¹²	17	M	fever	50 IU/L	31 IU/L	399 IU/L	132 IU/L	prednisone	recovered
Lankisch et al.¹³	30	F	fatigue, fever	NA	NA	861 U/L	120 U/L	prednisone	recovered
Sasae et al.¹⁴	20	F	fatigue	38 IU/L	61 IU/L	410 IU/L	NA	prednisone	recovered
Durant et al.¹⁵	18	F	fever, weight loss	NA	NA	NA	NA	prednisone	recovered
Durant et al.¹⁵	20	F	fever	NA	NA	NA	NA	prednisone	recovered

TA, Takayasu arteritis; AST, aspartate transferase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, γ-glutamyltransferase; NA, details not available.

Clinical course

The five cases in these four reports^12–15 showed that in TA patients with liver injury, the most common complaints were nonspecific symptoms, such as fatigue, intermittent fever, headache, weight loss, anorexia, nausea, and abdominal pain. The diagnosis was established through a combination of symptoms, physical examination, imaging results that indicated vasculitis, and liver biopsy.

Pathogenesis of liver injury in TA

The mechanism of liver injury in TA has never been discussed. The basic pathological feature of TA is granulomatous inflammation (Figure 1). It has been reported that the etiology of hepatic granulomas, including vasculitis and hepatic granuloma disease, could lead to biochemical abnormalities in the liver.^16,17 Thus, we conclude that TA causes liver injury via the formation of granulomas (Figure 2).

Figure 1.

Liver pathology in a patient with TA. Most of the mononuclear cells have infiltrated, and granulomas of different sizes were localized in the lobules. Multiple epithelioid cells aggregated in the granuloma, and a few mononuclear cells were observed in the granuloma. There was no fibrous envelope around the granuloma, and acid-fast staining was negative.

Figure 2.

Possible mechanisms of liver injury in TA.

Immune component

The exact pathogenic sequence of granuloma formation in TA is not completely understood, and functional dysregulation resulting from the immunological alterations may contribute to the formation of granulomas in TA. The immune response to pathogen exposure has been considered to be a potential etiological factor (Figure 3).

Figure 3.

Schematic representation of the possible mechanism of granuloma formation in Takayasu’s arteritis. TA lesions are mostly generated in the adventitia through the vasa vasorum. Different antigens such as infection stimuli trigger the expression of 65 kDa HSP, which initiates an inflammatory response. The expression of 65 kDa HSP in aortic tissue may contribute to the activation of dendritic cells. Dendritic cells expressing specific HLA molecules (Glu63 and Ser67) in the adventitia in response to a stimulus have not been identified. Dendritic cells activate T cells through Toll-like receptors. After interacting with dendritic cells, T cells increase activate macrophages and release IFN-γ and TNF-α, promoting prolonged multinucleated giant cell activation. Multinucleated giant cells cause granuloma formation, ultimately leading to tissue damage. Activated macrophage release IL-6, IL-23, VEGF (leading to neovascularization), and PDGF (which results in intimal proliferation). Th17 cells induced by IL-23 attract and activate neutrophils in the vessel wall, causing vascular lesions. IL-6 and IL-9, which likely contribute to vessel wall damage. γδ T cells and NK cells expressing the immune receptor NKG2D recognize the stress ligand MICA that is expressed on vascular smooth muscle, leading to damage in the intima layer. CD8+ T cells may also cause necrosis through the release of perforin. By activating endothelial cells and inducing complement-mediated cytotoxicity, AAECA may also contribute to the pathogenesis of TA.

Different studies have suggested that mechanisms that are mediated by humoral immunity and cell immunity are strongly implicated in inflammation and tissue damage in TA.¹⁸ T cells were reported to be present in greater amounts in the aorta of TA patients, and the T cells were associated with histological disease activity and with prednisone use in TA.¹⁹ The decrease in the number of T regulatory cells (Treg) cells, which is a T cell subset that is needed to maintain immune homeostasis, further indicates that the T cell-mediated immune response is involved.²⁰ In addition, other immune cell types, such as macrophages and natural killer (NK) cells, also infiltrate the tissue in TA.¹⁹ Seko et al.²¹ revealed that major histocompatibility class I chain-related A (MICA), which is induced by external stress and binds to NKG2D receptors on infiltrating cells, was increased in aortic tissue of patients with TA. Moreover, it has been proposed that the differential release of proinflammatory cytokines such as interleukin (IL)-23 may also have a substantial influence on TA pathogenesis.²² Serum concentrations of TNF-α, IL-6, IL-9, IL-18, and IL-17 in patients with TA are frequently observed to be higher than those in healthy people.^23,24 The IL-6 concentration is increased in the peripheral blood and aortic tissues of TA patients.²⁵ IL-6 has been proposed to induce fibrogenesis of aortic adventitial fibroblasts via the JAK2/STAT3 and JAK2/Akt pathways.²⁶ The effective treatment of refractory TA with tocilizumab, an anti-IL-6 receptor monoclonal antibody, further confirms the involvement of IL-6 in TA.²⁷

Moreover, although B lymphocytes are absent in TA lesions, the number and frequency of peripheral blood CD19(+)/CD20(−)/CD27(high) antibody-secreting cells (B cells) have been reported to be significantly higher in patients with active TA than in healthy donors; three patients with active refractory TA and expansion of plasmablasts were successfully treated with B cell depletion therapy.²⁸ Zanwar et al.²⁹ reported serum levels of B cell survival factors activation factor (BAFF) and A proliferation inducing ligand (APRIL) correlated with disease activity (Indian Takayasu Clinical Activity Score-ESR) or the TA damage score, suggesting a probable role for B cells in TA pathogenesis. Additionally, Mutoh et al.³⁰ reported that a 34-year-old man with TA who was refractory to four biologic agents had been successfully treated with an anti-CD20 monoclonal antibody (rituximab), and the outcome supports the hypothesis that B cell depletion therapy can be a useful option for refractory TA.

Genetic component

In addition to immune function studies, genome-wide association studies have revealed the heritability of TA in the human leukocyte antigen (HLA) region, and common susceptibility factors have also been reported in response-regulated genes.³¹

The HLA region, a 3.6-Mb segment of the human genome at 6p21, has been associated with more than 100 diseases and primarily with autoimmune diseases.³² Kitamura et al.³³ showed that the HLA-B52 molecule and the B39 molecule could contribute to different clinical manifestations by binding different antigenic peptides to cause inflammation. Thus, it is suggested that the HLA-B molecule may play an important role in pathogenesis or determining clinical manifestations of TA.³³ Another meta-analysis also demonstrated that the HLA-B*52 allele may significantly contribute to TA susceptibility.³⁴ Glu and Ser at positions 63 and 67, which have been identified as essential amino acid residues in the HLA-B molecule, are also thought to determine the patient’s susceptibility to TA.³⁵ Moreover, patients with HLA-B52 in Turkey seem to have more severe left ventricular involvement than those without it, further indicating a possible relationship between TA and HLA-B52.³⁶ Umemura and coworkers³⁷ revealed that KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. In another study, the HLA-B*27 subtype was reported to specifically determine targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.³⁸

Outside the HLA region, several genes that are involved in regulating the immune response have been associated with TA. Renauer et al.³⁹ identified novel genetic susceptibility loci for TA with a genome-wide level of significance in IL-6 (rs2069837). The role of IL-6 gene polymorphisms was also considered to be associated with susceptibility to hepatitis in a previous study.⁴⁰ IL-1 family member 10, which was recently renamed IL-38, exerts anti-inflammatory effects by effectively inhibiting inflammatory mediator production (IL-17A and IL-22).^41,42 Afzal et al.⁴³ also revealed that different IL-10 gene polymorphisms may lead to an imbalance between the proinflammatory and anti-inflammatory cytokine responses, which may influence the development of hepatitis. Nakajima et al.⁴⁴ reported the rs6871626 single nucleotide polymorphism in IL-12B may cause increased IL-12p40 and IL-12p70 expression. These enhanced cytokines might play roles in TA pathophysiology.⁴⁴ In Chinese Han hemodialysis patients, IL-12B polymorphisms were reported to potentially contribute to hepatitis C susceptibility.⁴⁵ Therefore, the involvement of these genes and single nucleotide polymorphisms might be important in the pathogenesis of liver injury in TA.

Infection

Compelling evidence strongly suggests that infections are significantly involved in the development of TA. Some authors have suggested that infection by several types of microorganisms, such as Mycobacterium tuberculosis and Chlamydia trachomatis, could be involved in TA pathogenesis, but supporting evidence remains inconclusive. In clinical studies, Zhang et al.⁴⁶ demonstrated that the percentage of tuberculosis (TB) history in patients with giant cell arteritis was higher than that in the Chinese general population. IS6110 (which is used to identify the M. tuberculosis complex) and HupB (which is used to establish the differences between M. tuberculosis and Mycobacterium bovis) genes have been reported have a higher frequency in aortic tissues of TA patients.⁴⁷ Patients with multidrug-resistant TB are generally considered to be at risk of hepatitis C infection.⁴⁸ Additionally, C. trachomatis has been investigated in association with Cogan’s syndrome (CS) and TA, but in most cases, this link remains hypothetical.^49,50 Sarcoidosis, which is a systemic granulomatous disease of unknown etiology that can affect any organ, was also recently reported to be concomitantly developed with TA, but it is not clear whether these findings are typical or a result of chance alone.^51,52 Hepatic granulomas are a common finding in systemic sarcoidosis, but most patients remain asymptomatic.⁵³ Fetzer et al.⁵⁴ revealed that sarcoidosis may present as liver dysfunction, cirrhosis, or portal hypertension. Sarcoid-related liver disease may progress and can manifest without, alongside, or significantly after a diagnosis of pulmonary disease.⁵⁴ Thus, although many infectious diseases may lead to liver injury in TA, the evidence remains insufficient and further research is required in the future.

Gut microbiota

Gut microbiota is involved in immune system development. The gut microbiota has been associated with a variety of human diseases, such as autoimmune encephalomyelitis and cancer.^55,56

An accumulating amount of evidence has shown that gut microbiota plays an important role in the development of autoimmune diseases such as autoimmune lupus.^57,58 The composition and function of gut microbiota have been reported to play an important role in the process of inflammatory bowel disease,⁵⁹ and Kawasaki disease, which is vasculitis of the small- and medium-sized vessels, has been reported to be associated with the HLA-B genotype.⁶⁰ Esposito et al.⁶¹ reported that a higher number of Gram-positive cocci (genera Streptococcus and Staphylococcus), Eubacterium, Peptostreptococcus, and HSP60-producing Gram-negative microbes have been found in stool samples from children with Kawasaki disease. Ye et al.⁶² revealed a distinct gut microbiome signature in Vogt–Koyanagi–Harada patients. Vogt–Koyanagi–Harada disease is a multisystemic autoimmune disorder that is characterized by granulomatous panuveitis, and it is associated with genotype HLA-DRA. Ye et al.⁶² showed an exacerbating effect of this gut microbiome on experimental autoimmune uveitis. Various microorganisms (both bacteria and viruses) have been detected in giant cell arteritis patients even in normal aortic tissues, suggesting that blood vessels may not be sterile but are inhabited by their own unique microbial ecosystem.⁶³ Additionally, a wide variety of bacteria, including oral bacteria, was found to colonize aortic aneurysms.⁶⁴ Therefore, vascular dysbiosis may also be involved in the development of TA.

Numerous studies suggest that alterations in human microbiota may be involved in the pathogenesis of vasculitides as a result of the aberrant activation of the innate and adaptive immune responses.⁶⁵ Akiyama et al.⁶⁶ thought that gut microbiota may be associated with HLA-B52-positive TA. In another study, gut microbiota was considered to be a new insight that was related to TA pathogenesis and that may contribute to the design of novel therapeutic approaches.⁶⁷

Thus, several studies have shown that the changes in gut microbiota may be related to the pathogenesis of vasculitis such as TA. However, research in this area is rare, and further research is needed to better understand the impact of microbiota dysbiosis on TA progression, and to develop prevention or treatment strategies.

Discussion

Currently, treatment of granulomatous liver disease (which is defined by the histologic findings on liver biopsy) depends on the underlying diagnosis, and it is still associated with many problems.⁶⁸ Kumar et al.⁵³ revealed that corticosteroid therapy may improve symptoms and liver chemistry but not alter the long-term outcome of hepatic sarcoidosis. Treatment of hepatic granulomata that is caused by primary biliary cirrhosis currently includes licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide).⁶⁹ These treatment methods can significantly improve liver function, after which the liver may produce bile acids that could regulate gut microbiota through activate farnesoid X receptor (FXR) via the gut–liver axis (Figure 4).⁷⁰ Glucocorticoids remain the major treatment method in patients with TA, but this therapy leads to many complications and some patients relapse and require immunosuppressive agents.⁷ Thus, there is an urgent need to better understand the mechanisms of liver injury in TA to develop novel and effective therapeutic strategies.

Figure 4.

Schematic depicting the potential interaction between gut microbiota and the liver. The composition and function of gut microbiota may be influenced by different factors such as genes and infection. After the onset of gut dysbiosis, the gut microbiota and their products may reach the liver through the portal circulation. Then, the gut microbiota causes an immune response in the liver and formation of granulomatous hepatitis. When liver function recovers to normal, the liver can regulate the gut microbiota composition by secretion of bile acid through activation of the farnesoid X receptor (FXR).

In this review, we summarized the clinical information and pathological features of liver injury in TA. Recognition of the importance of the immune response as a central role of liver injury in TA indicates that anti-inflammatory agents are required for treatment. Inflammation in liver injury can be treated with anti-inflammatory drugs such as prednisone. Genetic data support the role of genes throughout the course of TA and suggest that individualized treatment strategies are needed for future treatment of TA liver injury. During sarcoidosis, microbes or their products may trigger the immune response leading to sarcoid granuloma formation.⁷¹ The human microbiota was also reported to play an important role in pathogen colonization resistance, and it has been proposed to play a potential role in TB granuloma formation.⁷² In addition, fecal microbiota transplantation, which is a novel method to manipulate gut microbiota, was reported to be an effective therapy for inflammatory bowel disease and recurrent Clostridium difficile infection.^73,74 In patients with TA that was caused by gut microbiota dysbiosis, the use of fecal microflora transplantation to manipulate gut microbiota may become a new treatment method. Further study such as using high throughput sequencing on stool samples from TA patients is needed to clarify TA pathogenesis and to find novel treatment methods.

Footnotes

Authors contributions

KK wrote the manuscript. BC critically revised the manuscript. YS and YLL conceived the study. All authors approved the final manuscript.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Kai Kang

References

Zhang

Zhao

Wang

, et al. Targeting mechanistic target of rapamycin complex 1 restricts proinflammatory T cell differentiation and ameliorates Takayasu arteritis. Arthritis Rheumatol 2020; 72: 303–315.

Onen

and Akkoc

Epidemiology of Takayasu arteritis.

Presse Med 2017; 46: e197–e203.

Watanabe

Berry

Liang

, et al. Pathogenesis of giant cell arteritis and Takayasu arteritis-similarities and differences. Curr Rheumatol Rep 2020; 22: 68.

Dang

, et al. Pulmonary artery involvement in patients with Takayasu arteritis. J Rheumatol 2020; 47: 264–272.

Fan

Zhang

Cai

, et al. Clinical course, management, and outcomes of pediatric Takayasu arteritis initially presenting with hypertension: a 16-year overview. Am J Hypertens 2019; 32: 1021–1029.

Yachoui

Kreidy

Siorek

, et al. Successful treatment with ustekinumab for corticosteroid- and immunosuppressant-resistant Takayasu’s arteritis. Scand J Rheumatol 2018; 47: 246–247.

Mutoh

Shirai

Fujii

, et al. Insufficient use of corticosteroids without immunosuppressants results in higher relapse rates in Takayasu arteritis. J Rheumatol 2020; 47: 255–263.

Ohigashi

Tamura

Ebana

, et al. Effects of immunosuppressive and biological agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 2017; 69: 774–778.

Cui

Dai

, et al. Efficacy and safety of leflunomide treatment in Takayasu arteritis: case series from the East China cohort. Semin Arthritis Rheum 2020; 50: 59–65.

10.

Gudbrandsson

Molberg

and Palm

TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis: an observational, population-based time trend study. Arthritis Res Ther 2017; 19: 99.

11.

Heinemann

Omansen

Hennigs

, et al. Relapsing cutaneous leishmaniasis in a patient requiring TNF-α-inhibitor Infliximab for Takayasu-arteritis: case report and review of the literature. Travel Med Infect Dis 2020; 37: 101700.

12.

Yotsuyanagi

Chikatsu

Kaneko

, et al. Takayasu’s arteritis in prepulseless stage manifesting lymph node swelling and hepatosplenomegaly. Intern Med 1995; 34: 455–459.

13.

Lankisch

Scolapio

Thistle

, et al. Elevated liver enzymes preceding vessel involvement in Takayasu's arteritis. J Hepatol 1999; 30: 349–350.

14.

Sasae

Morita

Sakuta

, et al. Abdominal pain as the initial presentation of Takayasu arteritis. Mod Rheumatol 2008; 18: 496–498.

15.

Durant

Martin

Hervier

, et al. Takayasu arteritis associated with hepatic sinusoidal dilatation. Ann Hepatol 2011; 10: 559–561.

16.

Lamps

LW.

Hepatic granulomas: a review with emphasis on infectious causes.

Arch Pathol Lab Med 2015; 139: 867–875.

17.

Almadi

Aljebreen

Sanai

, et al. New insights into gastrointestinal and hepatic granulomatous disorders. Nat Rev Gastroenterol Hepatol 2011; 8: 455–466.

18.

Arnaud

Haroche

Mathian

, et al. Pathogenesis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev 2011; 11: 61–67.

19.

Dos Santos

Artigiani Neto

Mangueira

, et al. Associations between clinical features and therapy with macrophage subpopulations and T cells in inflammatory lesions in the aorta from patients with Takayasu arteritis. Clin Exp Immunol 2020.

20.

Samson

and Bonnotte

Pathogenesis of large vessel vasculitis. Rev Med Interne 2016; 37: 264–273.

21.

Seko

Sugishita

Sato

, et al. Expression of costimulatory molecules (4-1BBL and Fas) and major histocompatibility class I chain-related A (MICA) in aortic tissue with Takayasu’s arteritis. J Vasc Res 2004; 41: 84–90.

22.

Yang

Meng

, et al. Lack of association between polymorphisms in interleukin (IL)-12, IL-12R, IL-23, IL-23R genes and Takayasu arteritis in a Chinese population. Inflamm Res 2016; 65: 543–550.

23.

Tamura

Maejima

Tezuka

, et al. Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol 2017; 70: 278–285.

24.

Pan

Gao

, et al. IL-9-producing Th9 cells may participate in pathogenesis of Takayasu’s arteritis. Clin Rheumatol 2016; 35: 3031–3036.

25.

Kong

Sun

, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol 2016; 34: S21–S27.

26.

Kong

, et al. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol 2018; 36: 62–72.

27.

Yano

Osanami

Shimizu

, et al. Utility and safety of tocilizumab in Takayasu arteritis with severe heart failure and muscle wasting. ESC Heart Fail 2019; 6: 894–897.

28.

Hoyer

Mumtaz

Loddenkemper

, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71: 75–79.

29.

Zanwar

Jain

Gupta

, et al. Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis. Clin Rheumatol 2018; 37: 3439–3442.

30.

Mutoh

Ishii

Shirai

, et al. Refractory Takayasu arteritis successfully treated with rituximab: case-based review. Rheumatol Int 2019; 39: 1989–1994.

31.

Renauer

and Sawalha

AH.

The genetics of Takayasu arteritis.

Presse Med 2017; 46: e179–e187.

32.

Hosomichi

Shiina

Tajima

, et al. The impact of next-generation sequencing technologies on HLA research. J Hum Genet 2015; 60: 665–673.

33.

Kitamura

Kobayashi

Kimura

, et al. Association of clinical manifestations with HLA-B alleles in Takayasu arteritis. Int J Cardiol 1998: S121–S126.

34.

Chen

Luan

, et al. Relationship of HLA-B*51 and HLA-B*52 alleles and TNF-α-308A/G polymorphism with susceptibility to Takayasu arteritis: a meta-analysis. Clin Rheumatol 2017; 36: 173–181.

35.

Kimura

Kitamura

Date

, et al. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol 1996; 54: S61–S69.

36.

Kasuya

Hashimoto

and Numano

Left ventricular dysfunction and HLA Bw52 antigen in Takayasu arteritis. Heart Vessels Suppl 1992; 7: 116–119.

37.

Umemura

Joshita

Saito

, et al. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. JHEP Rep 2019; 1: 353–360.

38.

Nitschke

Barriga

Schmidt

, et al. HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. J Hepatol 2014; 60: 22–29.

39.

Renauer

Saruhan-Direskeneli

Coit

, et al. Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu arteritis in a genome-wide association study. Arthritis Rheumatol 2015; 67: 1361–1368.

40.

El-Maadawy

Talaat

Ahmed

, et al. Interleukin-6 promotor gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Hum Immunol 2019; 80: 208–214.

41.

Van De Veerdonk

Stoeckman

, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 2012; 109: 3001–3005.

42.

Rudloff

Godsell

Nold-Petry

, et al. Brief report: interleukin-38 exerts antiinflammatory functions and is associated with disease activity in systemic Lupus Erythematosus. Arthritis Rheumatol 2015; 67: 3219–3225.

43.

Afzal

Tahir

Salman

, et al. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries 2011; 5: 473–479.

44.

Nakajima

Yoshifuji

Shimizu

, et al. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Res Ther 2017; 19: 197.

45.

Zhu

Wang

Zhang

, et al. Relationships between interleukin-12B and interleukin-10 gene polymorphisms and hepatitis C in Chinese Han hemodialysis patients. Ren Fail 2015; 37: 505–510.

46.

Zhang

Wang

Yin

, et al. Tuberculosis infection in Chinese patients with giant cell arteritis. Sci Rep 2019; 9: 14364.

47.

Soto

Del Carmen Ávila-Casado

Huesca-Gómez

, et al. Detection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovis in the aortic tissue of patients with Takayasu’s arteritis. BMC Infect Dis 2012; 12: 194.

48.

Seung

Franke

Hewison

, et al. High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol 2020; 72: 1028–1029.

49.

Kawasaki

Uehara

and Kawana

Cutaneous vasculitis in Cogan’s syndrome: a report of two cases associated with Chlamydia infection.

J Nippon Med Sch 2018; 85: 172–177.

50.

Fujita

Hatachi

and Yagita

Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases. Lupus 2009; 18: 164–168.

51.

Chapelon-Abric

Saadoun

Marie

, et al. Sarcoidosis with Takayasu arteritis: a model of overlapping granulomatosis. A report of seven cases and literature review. Int J Rheum Dis 2018; 21: 740–745.

52.

Saha

Burns

Foulke

, et al. Coexistent Takayasu arteritis and sarcoidosis: a case report and review of the literature. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36: 311–317.

53.

Kumar

and Herrera

JL.

Sarcoidosis and the liver.

Clin Liver Dis 2019; 23: 331–343.

54.

Fetzer

Rees

Dasyam

, et al. Hepatic sarcoidosis in patients presenting with liver dysfunction: imaging appearance, pathological correlation and disease evolution. Eur Radiol 2016; 26: 3129–3137.

55.

Chen

Liu

, et al. Clostridium butyricum gut microbiota interventions with and norfloxacin modulate immune response in experimental autoimmune encephalomyelitis Mice. Front Immunol 2019; 10: 1662.

56.

Frankel

Deshmukh

Reddy

, et al. Cancer immune checkpoint inhibitor therapy and the gut microbiota. Integr Cancer Ther 2019; 18: 1871064811.

57.

Zhang

Chen

Zhao

, et al. The gut microbiota: emerging evidence in autoimmune diseases. Trends Mol Med 2020; 26: 862–873.

58.

Neuman

and Koren

The gut microbiota: a possible factor influencing systemic lupus erythematosus.

Curr Opin Rheumatol 2017; 29: 374–377.

59.

Knox

Forbes

Peterson

, et al. The gut microbiome in Inflammatory bowel disease: lessons learned from other immune-mediated inflammatory diseases. Am J Gastroenterol 2019; 114: 1051–1070.

60.

Kim

Yun

, et al. A genome-wide association analysis identifies NMNAT2 and HCP5 as susceptibility loci for Kawasaki disease. J Hum Genet 2017; 62: 1023–1029.

61.

Esposito

Polinori

and Rigante

The gut microbiota-host partnership as a potential driver of Kawasaki syndrome.

Front Pediatr 2019; 7: 124.

62.

Zhang

, et al. Altered gut microbiome composition in patients with Vogt–Koyanagi–Harada disease. Gut Microbes 2020; 11: 539–555.

63.

Clifford

Hoffman

G S.

Evidence for a vascular microbiome and its role in vessel health and disease.

Curr Opin Rheumatol 2015; 27: 397–405.

64.

Marques Da Silva

Caugant

Eribe

, et al. Bacterial diversity in aortic aneurysms determined by 16S ribosomal RNA gene analysis. J Vasc Surg 2006; 44: 1055–1060.

65.

Talotta

Atzeni

Ditto

, et al. The microbiome in connective tissue diseases and vasculitides: an updated narrative review. J Immunol Res 2017; 2017: 6836498.

66.

Akiyama

Kaneko

and Takeuchi

Does microbiome contribute to HLA-B52-positive Takayasu arteritis?

Mod Rheumatol 2020; 30: 213–217.

67.

Espinoza

and Matsumura

New insights on the pathogenesis of Takayasu arteritis: revisiting the microbial theory.

Pathogens 2018; 7: 73.

68.

Flamm

SL.

Granulomatous liver disease.

Clin Liver Dis 2012; 16: 387–396.

69.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67: 145–172.

70.

Pathak

Xie

Nichols

, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 2018; 68: 1574–1588.

71.

Inaoka

Shono

Kamada

, et al. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci 2019; 26: 45.

72.

Balcells

Yokobori

Hong

, et al. The lung microbiome, vitamin D, and the tuberculous granuloma: a balance triangle. Microb Pathog 2019; 131: 158–163.

73.

Hvas

Dahl Jørgensen

Jørgensen

, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 2019; 156: 1324–1332.

74.

Syal

Kashani

and Shih

DQ.

Fecal microbiota transplantation in inflammatory bowel disease: a primer for internists.

Am J Med 2018; 131: 1017–1024.

Pathogenesis of liver injury in Takayasu arteritis: advanced understanding leads to new horizons

Abstract

Keywords

Introduction

Methods

Clinical course

Pathogenesis of liver injury in TA

Immune component

Genetic component

Infection

Gut microbiota

Discussion

Footnotes

Authors contributions

Declaration of conflicting interest

Funding

ORCID iD

References